Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics.

Sukumaran S, Zhang C, Leipold DD, Saad OM, Xu K, Gadkar K, Samineni D, Wang B, Milojic-Blair M, Carrasco-Triguero M, Rubinfeld B, Fielder P, Lin K, Ramanujan S.

AAPS J. 2017 Jan;19(1):130-140. doi: 10.1208/s12248-016-9993-z. Epub 2016 Sep 27.

PMID:
27679517
2.
3.

Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.

Wang J, Iyer S, Fielder PJ, Davis JD, Deng R.

Biopharm Drug Dispos. 2016 Mar;37(2):51-65. doi: 10.1002/bdd.1952. Epub 2015 May 15. Review.

PMID:
25869767
4.

A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations.

Gadkar K, Budha N, Baruch A, Davis JD, Fielder P, Ramanujan S.

CPT Pharmacometrics Syst Pharmacol. 2014 Nov 26;3:e149. doi: 10.1038/psp.2014.47.

5.

A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations.

Gadkar K, Budha N, Baruch A, Davis JD, Fielder P, Ramanujan S.

CPT Pharmacometrics Syst Pharmacol. 2014 Nov;3(11):1-9. doi: 10.1038/psp.2014.47.

6.

Comparative physiology of mice and rats: radiometric measurement of vascular parameters in rodent tissues.

Boswell CA, Mundo EE, Ulufatu S, Bumbaca D, Cahaya HS, Majidy N, Van Hoy M, Schweiger MG, Fielder PJ, Prabhu S, Khawli LA.

Mol Pharm. 2014 May 5;11(5):1591-8. doi: 10.1021/mp400748t. Epub 2014 Apr 21.

PMID:
24702191
7.

Quantitative cumulative biodistribution of antibodies in mice: effect of modulating binding affinity to the neonatal Fc receptor.

Yip V, Palma E, Tesar DB, Mundo EE, Bumbaca D, Torres EK, Reyes NA, Shen BQ, Fielder PJ, Prabhu S, Khawli LA, Boswell CA.

MAbs. 2014 May-Jun;6(3):689-96. doi: 10.4161/mabs.28254. Epub 2014 Feb 26.

8.

Enhanced tumor retention of a radiohalogen label for site-specific modification of antibodies.

Boswell CA, Marik J, Elowson MJ, Reyes NA, Ulufatu S, Bumbaca D, Yip V, Mundo EE, Majidy N, Van Hoy M, Goriparthi SN, Trias A, Gill HS, Williams SP, Junutula JR, Fielder PJ, Khawli LA.

J Med Chem. 2013 Dec 12;56(23):9418-26. doi: 10.1021/jm401365h. Epub 2013 Nov 5.

PMID:
24131491
9.
10.

A strategy for risk mitigation of antibodies with fast clearance.

Hötzel I, Theil FP, Bernstein LJ, Prabhu S, Deng R, Quintana L, Lutman J, Sibia R, Chan P, Bumbaca D, Fielder P, Carter PJ, Kelley RF.

MAbs. 2012 Nov-Dec;4(6):753-60. doi: 10.4161/mabs.22189.

11.

Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies.

Mortensen DL, Prabhu S, Stefanich EG, Kadkhodayan-Fischer S, Gelzleichter TR, Baker D, Jiang J, Wallace K, Iyer S, Fielder PJ, Putnam WS.

MAbs. 2012 Nov-Dec;4(6):724-31. doi: 10.4161/mabs.22216.

12.

Vascular physiology and protein disposition in a preclinical model of neurodegeneration.

Boswell CA, Mundo EE, Johnstone B, Ulufatu S, Schweiger MG, Bumbaca D, Fielder PJ, Prabhu S, Khawli LA.

Mol Pharm. 2013 May 6;10(5):1514-21. doi: 10.1021/mp3004786. Epub 2013 Feb 25.

PMID:
23383983
13.

Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations.

Boswell CA, Bumbaca D, Fielder PJ, Khawli LA.

AAPS J. 2012 Sep;14(3):612-8. doi: 10.1208/s12248-012-9374-1. Epub 2012 May 31.

14.

Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics.

Bumbaca D, Boswell CA, Fielder PJ, Khawli LA.

AAPS J. 2012 Sep;14(3):554-8. doi: 10.1208/s12248-012-9369-y. Epub 2012 May 18. Review.

15.

Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration.

Zheng Y, Tesar DB, Benincosa L, Birnböck H, Boswell CA, Bumbaca D, Cowan KJ, Danilenko DM, Daugherty AL, Fielder PJ, Grimm HP, Joshi A, Justies N, Kolaitis G, Lewin-Koh N, Li J, McVay S, O'Mahony J, Otteneder M, Pantze M, Putnam WS, Qiu ZJ, Ruppel J, Singer T, Stauch O, Theil FP, Visich J, Yang J, Ying Y, Khawli LA, Richter WF.

MAbs. 2012 Mar-Apr;4(2):243-55. doi: 10.4161/mabs.4.2.19387. Epub 2012 Mar 1.

16.

Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice.

Deng R, Meng YG, Hoyte K, Lutman J, Lu Y, Iyer S, DeForge LE, Theil FP, Fielder PJ, Prabhu S.

MAbs. 2012 Jan-Feb;4(1):101-9. doi: 10.4161/mabs.4.1.18543.

17.

Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model.

Pastuskovas CV, Mundo EE, Williams SP, Nayak TK, Ho J, Ulufatu S, Clark S, Ross S, Cheng E, Parsons-Reponte K, Cain G, Van Hoy M, Majidy N, Bheddah S, dela Cruz Chuh J, Kozak KR, Lewin-Koh N, Nauka P, Bumbaca D, Sliwkowski M, Tibbitts J, Theil FP, Fielder PJ, Khawli LA, Boswell CA.

Mol Cancer Ther. 2012 Mar;11(3):752-62. doi: 10.1158/1535-7163.MCT-11-0742-T. Epub 2012 Jan 5.

18.

Equilibrative nucleoside transporter 3 deficiency perturbs lysosome function and macrophage homeostasis.

Hsu CL, Lin W, Seshasayee D, Chen YH, Ding X, Lin Z, Suto E, Huang Z, Lee WP, Park H, Xu M, Sun M, Rangell L, Lutman JL, Ulufatu S, Stefanich E, Chalouni C, Sagolla M, Diehl L, Fielder P, Dean B, Balazs M, Martin F.

Science. 2012 Jan 6;335(6064):89-92. doi: 10.1126/science.1213682. Epub 2011 Dec 15.

19.

Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice.

Bumbaca D, Xiang H, Boswell CA, Port RE, Stainton SL, Mundo EE, Ulufatu S, Bagri A, Theil FP, Fielder PJ, Khawli LA, Shen BQ.

Br J Pharmacol. 2012 May;166(1):368-77. doi: 10.1111/j.1476-5381.2011.01777.x.

20.

A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis.

Owczarczyk K, Lal P, Abbas AR, Wolslegel K, Holweg CT, Dummer W, Kelman A, Brunetta P, Lewin-Koh N, Sorani M, Leong D, Fielder P, Yocum D, Ho C, Ortmann W, Townsend MJ, Behrens TW.

Sci Transl Med. 2011 Sep 21;3(101):101ra92. doi: 10.1126/scitranslmed.3002432.

21.

Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats.

Boswell CA, Mundo EE, Zhang C, Bumbaca D, Valle NR, Kozak KR, Fourie A, Chuh J, Koppada N, Saad O, Gill H, Shen BQ, Rubinfeld B, Tibbitts J, Kaur S, Theil FP, Fielder PJ, Khawli LA, Lin K.

Bioconjug Chem. 2011 Oct 19;22(10):1994-2004. doi: 10.1021/bc200212a. Epub 2011 Oct 3.

PMID:
21913715
22.

Effects of anti-VEGF on predicted antibody biodistribution: roles of vascular volume, interstitial volume, and blood flow.

Boswell CA, Ferl GZ, Mundo EE, Bumbaca D, Schweiger MG, Theil FP, Fielder PJ, Khawli LA.

PLoS One. 2011 Mar 15;6(3):e17874. doi: 10.1371/journal.pone.0017874.

23.

Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study.

Zheng Y, Scheerens H, Davis JC Jr, Deng R, Fischer SK, Woods C, Fielder PJ, Stefanich EG.

Clin Pharmacol Ther. 2011 Feb;89(2):283-90. doi: 10.1038/clpt.2010.311. Epub 2010 Dec 29.

PMID:
21191378
24.

Effects of charge on antibody tissue distribution and pharmacokinetics.

Boswell CA, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, Khawli LA.

Bioconjug Chem. 2010 Dec 15;21(12):2153-63. doi: 10.1021/bc100261d. Epub 2010 Nov 5. Review.

PMID:
21053952
25.

Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?

Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S.

MAbs. 2011 Jan-Feb;3(1):61-6. Epub 2011 Jan 1.

26.

Effect of immune complex formation on the distribution of a novel antibody to the ovarian tumor antigen CA125.

Pastuskovas CV, Mallet W, Clark S, Kenrick M, Majidy M, Schweiger M, Van Hoy M, Tsai SP, Bennett G, Shen BQ, Ross S, Fielder P, Khawli L, Tibbitts J.

Drug Metab Dispos. 2010 Dec;38(12):2309-19. doi: 10.1124/dmd.110.034330. Epub 2010 Sep 7.

27.

Development and evaluation of a novel method for preclinical measurement of tissue vascular volume.

Boswell CA, Ferl GZ, Mundo EE, Schweiger MG, Marik J, Reich MP, Theil FP, Fielder PJ, Khawli LA.

Mol Pharm. 2010 Oct 4;7(5):1848-57. doi: 10.1021/mp100183k. Epub 2010 Aug 12.

PMID:
20704296
28.

Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice.

Jumbe NL, Xin Y, Leipold DD, Crocker L, Dugger D, Mai E, Sliwkowski MX, Fielder PJ, Tibbitts J.

J Pharmacokinet Pharmacodyn. 2010 Jun;37(3):221-42. doi: 10.1007/s10928-010-9156-2. Epub 2010 Apr 28.

PMID:
20424896
29.

Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys.

Deng R, Loyet KM, Lien S, Iyer S, DeForge LE, Theil FP, Lowman HB, Fielder PJ, Prabhu S.

Drug Metab Dispos. 2010 Apr;38(4):600-5. doi: 10.1124/dmd.109.031310. Epub 2010 Jan 13.

30.

Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays.

Boyd ZS, Wu QJ, O'Brien C, Spoerke J, Savage H, Fielder PJ, Amler L, Yan Y, Lackner MR.

Mol Cancer Ther. 2008 Dec;7(12):3695-706. doi: 10.1158/1535-7163.MCT-08-0810. Epub 2008 Dec 3.

31.

Evidence for an asialoglycoprotein receptor on nonparenchymal cells for O-linked glycoproteins.

Stefanich EG, Ren S, Danilenko DM, Lim A, Song A, Iyer S, Fielder PJ.

J Pharmacol Exp Ther. 2008 Nov;327(2):308-15. doi: 10.1124/jpet.108.142232. Epub 2008 Aug 26.

32.

Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody.

Putnam WS, Li J, Haggstrom J, Ng C, Kadkhodayan-Fischer S, Cheu M, Deniz Y, Lowman H, Fielder P, Visich J, Joshi A, Jumbe NS.

AAPS J. 2008 Jun;10(2):425-30. doi: 10.1208/s12248-008-9045-4. Epub 2008 Aug 7. Review.

33.

Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers.

Ng CM, Stefanich E, Anand BS, Fielder PJ, Vaickus L.

Pharm Res. 2006 Jan;23(1):95-103. Epub 2006 Nov 30.

PMID:
16308668
34.

Efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency.

Hoffman AR, Biller BM, Cook D, Baptista J, Silverman BL, Dao L, Attie KM, Fielder P, Maneatis T, Lippe B; Genentech Adult Growth Hormone Deficiency Study Group.

J Clin Endocrinol Metab. 2005 Dec;90(12):6431-40. Epub 2005 Sep 13.

PMID:
16159930
35.

Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis.

Vugmeyster Y, Beyer J, Howell K, Combs D, Fielder P, Yang J, Qureshi F, Sandlund B, Kawaguchi L, Dummer W, Lowman H, McKeever K.

J Immunother. 2005 May-Jun;28(3):212-9.

PMID:
15838377
36.

Tissue distribution and receptor-mediated clearance of anti-CD11a antibody in mice.

Coffey GP, Fox JA, Pippig S, Palmieri S, Reitz B, Gonzales M, Bakshi A, Padilla-Eagar J, Fielder PJ.

Drug Metab Dispos. 2005 May;33(5):623-9. Epub 2005 Jan 26.

37.

Pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient children.

Kemp SF, Fielder PJ, Attie KM, Blethen SL, Reiter EO, Ford KM, Marian M, Dao LN, Lee HJ, Saenger P.

J Clin Endocrinol Metab. 2004 Jul;89(7):3234-40.

PMID:
15240597
38.

In vitro internalization, intracellular transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells.

Coffey GP, Stefanich E, Palmieri S, Eckert R, Padilla-Eagar J, Fielder PJ, Pippig S.

J Pharmacol Exp Ther. 2004 Sep;310(3):896-904. Epub 2004 Jun 9.

39.

The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient adults.

Cook DM, Biller BM, Vance ML, Hoffman AR, Phillips LS, Ford KM, Benziger DP, Illeperuma A, Blethen SL, Attie KM, Dao LN, Reimann JD, Fielder PJ.

J Clin Endocrinol Metab. 2002 Oct;87(10):4508-14.

PMID:
12364427
40.

Sustained delivery of human growth hormone from a novel gel system: SABER.

Okumu FW, Dao le N, Fielder PJ, Dybdal N, Brooks D, Sane S, Cleland JL.

Biomaterials. 2002 Nov;23(22):4353-8.

PMID:
12219825
41.

Index of suspicion. Case 2. Diagnosis: Norrie disease.

Veeramachaneni VV, Fielder PN.

Pediatr Rev. 2001 Jun;22(6):211-5. No abstract available.

PMID:
11436222
42.

Dose schedule of recombinant murine thrombopoietin prior to myelosuppressive and myeloablative therapy in mice.

Stefanich EG, Carlson-Zermeno CC, McEvoy K, Reich M, Fielder PJ.

Cancer Chemother Pharmacol. 2001;47(1):70-7.

PMID:
11221965
43.

Binding protein-3-selective insulin-like growth factor I variants: engineering, biodistributions, and clearance.

Dubaquié Y, Mortensen DL, Intintoli A, Hogue DA, Nakamura G, Rancatore P, Lester P, Sadick MD, Filvaroff E, Fielder PJ, Lowman HB.

Endocrinology. 2001 Jan;142(1):165-73.

PMID:
11145579
44.

The efficacy of recombinant TPO in murine And nonhuman primate models for myelosuppression and stem cell transplantation.

Wagemaker G, Neelis KJ, Hartong SCC, Wognum AW, Thomas GR, Fielder PJ, Eaton DL.

Stem Cells. 1998;16 Suppl 2:127-41. Review.

45.

The efficacy of recombinant thrombopoietin in murine and nonhuman primate models for radiation-induced myelosuppression and stem cell transplantation.

Wagemaker G, Neelis KJ, Hartong SC, Wognum AW, Thomas GR, Fielder PJ, Eaton DL.

Stem Cells. 1998;16(6):375-86. Review.

47.

Binding and regulation of thrombopoietin to human megakaryocytes.

Sato T, Fuse A, Niimi H, Fielder PJ, Avraham H.

Br J Haematol. 1998 Mar;100(4):704-11.

PMID:
9531337
49.

Effect of insulin-like growth factor binding proteins on the response of proximal tubular cells to insulin-like growth factor-I.

Yap J, Tsao T, Fawcett J, Fielder PJ, Keller GA, Rabkin R.

Kidney Int. 1997 Nov;52(5):1216-23.

50.

Regulation of the serum concentration of thrombopoietin in thrombocytopenic NF-E2 knockout mice.

Shivdasani RA, Fielder P, Keller GA, Orkin SH, de Sauvage FJ.

Blood. 1997 Sep 1;90(5):1821-7.

Supplemental Content

Loading ...
Support Center